A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children-Reference-Cited by-同舟云学术

A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children

Published:2023-01 Issue:5 Volume:41 Page:1153-1160
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Cutland Clare L.,Peyrani Paula,Webber Chris,Newton Ryan,Cutler Mark,Perez John L.

Funder

Pfizer Inc

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference26 articles.

1. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP);Cohn;MMWR Recomm Rep,2013

2. Invasive Meningococcal Disease in the Vaccine Era;Nadel;Front Pediatr,2018

3. European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases, https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases; 2018 [accessed October 27, 2022].

4. US Centers for Disease Control and Prevention C. Enhanced Meningococcal Disease Surveillance Report, CDC, https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2019.pdf; 2019 [accessed October 27, 2022].

5. Declining Incidence of Invasive Meningococcal Disease in South Africa: 2003–2016;Meiring;Clin Infect Dis,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review;Journal of Infection;2024-09

2. Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination;Expert Review of Vaccines;2024-06-07